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Abstract: The recommendations of the current guidelines and the position papers of professional 
societies from the European Society of Cardiology/European Society of Cardiothoracic Surgeons (ESC), 
the American College of Cardiology/American Heart Association/Society of Thoracic Surgeon (ACC/
AHA/STS) and American Association of Thoracic Surgeon (AATS) regarding management of patients with 
valvular heart endocarditis were updated over the past decade. However, some of the recommendations 
appear to contradict one another. Given the changing paradigms on how the disease manifests, our aim was 
to review the respective guidelines and highlight these differences whilst drawing attention to the subsequent 
studies from which they were derived. In particular, concerns regarding antibiotic prophylaxis and therapy, 
imaging modality for diagnosis and follow-up, cerebrovascular sequalae and timing of surgery are appraised 
in detail. We also identified the novel techniques used such as transcatheter therapies and advances in 
imaging modalities used for diagnosis and treatment of this condition. The lack of randomised control trials 
(RCTs) does raise several issues regarding applicability of findings in day-to-day practice. Therefore, the 
focus of upcoming studies should be on clearly defined multicenter RCTs to provide more robust evidence 
for the management and treatment of infective endocarditis as future guidelines will be based on the 
outcomes of these trials. 
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Introduction
The recommendations of the current guidelines and the 
position papers of professional societies from the European 
Society of Cardiology/European Society of Cardiothoracic 
Surgeons (ESC), the American College of Cardiology/
American Heart Association/Society of Thoracic Surgeon 
(ACC/AHA/STS) and American Association of Thoracic 
Surgeon (AATS) regarding management of patients 
with valvular heart endocarditis were updated in 2014 
(1,2), 2015 (3) and again in 2016 (4) and 2017 (5,6) 
respectively. There are important differences within the 
recommendations relating to the management of patients 
with heart valve endocarditis (HVE), as with updated 
evidence via the publication of several reports from 
professional society recommendations. This study aims to 
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compare the recommendations by current guidelines and 
the position papers of professional societies with regards 
to management of patients with HVE. This review is 
focused on the differences between the two guidelines 
developed, by cardiologists and cardiac surgeons, and its 
purpose is to summarize new data that addresses some of 
the ongoing debates. The authors present the following 
article in accordance with the Narrative Review reporting 
checklist (available at http://dx.doi.org/10.21037/atm-20-
3739).
Class of recommendation (COR) and level or 
quality of evidence
The implementation of the COR and level of evidence 
(LOE) for the clinical strategy, intervention, treatment 
or diagnostic tests in patient care with HVE is generally 
addressed in prophylaxis, diagnosis and management 
which includes the choice of the best valve substitute 
and the timing for surgery as well as the prevention of 
complications. 
The focus of the guidelines for the management of 
patients with infectious disease of the heart valves is 
represented by the diagnosis and management of adult 
patients in whom the infection of the heart valve has 
occurred. The field of HVE is rapidly progressing, with 
updated knowledge about the natural history of patients 
with valvular endocarditis, diagnostic imaging advances 
and improvements in catheter-based interventions 
alongside standard surgery. Several randomized controlled 
trials  (RCTs) were highlighted in the guidelines, 
specifically with regards to the results on the timeliness 
of intervention, on the choice of antibiotic treatment and 
prevention of neurological complications. The main areas 
of change include indications for transcatheter aortic 
valve replacement (TAVR), for sutureless and for better 
management of patients with prosthetic valve endocarditis. 
The evidence also highlights a significant variability in 
HVE presentation and difficulty in establishing unequivocal 
clinical practice. Indeed, the recommendations from 
the position papers of professional societies are based 
on observational cohort studies or few individual RCTs 
rather than multicenter RCTs or patient-level combined 
analysis of RCTs. Figure 1 denotes the COR and the LOE 
that establishes the degree of choice for a treatment. It is 
important to point out that COR and LOE are dictated 
separately. When a recommendation is graded as Level C 
it is not universally considered as a weak recommendation. 
In fact, many of the therapeutic addresses that are given in 
the guidelines and professional societies recommendations 
originate from non-randomized studies. However, RCTs 
provide clear consensus for the application of a treatment 
Figure 1 Class of recommendation (COR) and the level of evidence (LOE) that establishes the degree of choice for a treatment.
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and therefore determine its effectiveness and safety 
(Figure 1).
The literature is scarce on data from randomized studies 
classified as LOE A that address a systematic approach 
not only for the choice of ideal substitute for IE but also 
with regards to the choice of prosthetic heart valve. It is 
indisputable that the LOE is useful to orient the timing 
and choices of the prosthetic heart valve in endocarditis. 
Analyzing the guidelines, we can observe that 6.7% of 
evidence by ACC/AHA (1,6) is Class I and 3% of ESC 
(3,5) is Class IIa. The LOE B based on recommendations 
is measured at 57% for ACC/AHA and 18% for ESC while 
the LOE C based on recommendations is measured at 
36.3% for ACC/AHA and to 79% for ESC guidelines 
Controversies regarding management of patients 
with HVE
Effects of changing guidelines on the incidence of IE
In the case of IE, the AHA/ACC guidelines for antibiotic 
prophylaxis are restrictive in the United States. Prophylaxis 
is indicated in patients who have received a prosthetic valve, 
CHD with an episode of IE, or in recipients of cardiac 
transplantation in whom valvulopathy has developed (7). 
DeSimone et al. (8,9), using data from the Rochester 
Epidemiological Project, analyzed the incidence of IE due 
to viridans group streptococci before and after the change 
of prophylaxis guidelines. The authors found no significant 
increase in the incidence and, in contrast, emphasized a 
decrease of 3.6 per 100,000/year from 1999 to 2002 to 
1.5 per 100,000 person-years from 2011–2013. Similarly, 
two reports performed on the Canadian population (10) 
and the United States (11) who underwent prophylactic 
treatment for IE, found no evidence for a change point in 
the incidence of IE to coincide with modified ACC/AHA 
guidelines. The most relevant studies that contrast with 
AHA/ACC are two national epidemiological studies from 
the United States and the United Kingdom which raised 
some concerns. 
Pant et al. (12), using the Nationwide Inpatient Sample, 
revealed that although they showed a statistically significant 
increase in the incidence of IE caused by streptococci, they 
were unable to identify significant changes in the trend, 
with a growing curve, both in total admissions and in the 
number of patients with IE due to S aureus. It should be 
noted that this study included non-homogeneous groups 
because of the incidence calculations in which both groups, 
non-viridans streptococci and enterococci were evaluated. 
The weakness lies in the fact that the new change point 
analysis was not carried out to confirm that the change in 
the rate coincided with the ACC/AHA amended guidelines. 
In addition, the investigators did not have access to the 
prescription data of antibiotic prophylaxis to confirm that 
this rate had decreased.
 In the UK (13) there is a marked restriction on the use 
of antibiotic prophylaxis. The national stance, since March 
2008, is to advise against the use of antibiotic prophylaxis. 
Initial analysis did not report an increase in the incidence 
of IE. The effects of the restriction on the use of antibiotics 
in IE prophylaxis are published in a 2015 study (14). In an 
extended analysis, the hospital discharge diagnoses were 
examined and reported by the National Health Service 
until 2013. Antibiotic prophylaxis decreased from 10,900 
prescriptions per month to 2,236 prescriptions per month 
after the introduction of the UK National Institute for 
Health and Care Excellence (NICE) guidelines. In parallel, 
there was a significant increase (above the expected trend) 
in the number of cases of IE, of 0.11 cases per 10 million 
people (or another 35 cases in England) per month. The 
statistical analysis identified June 2008 (3 months after 
the implementation of the new guidelines for the use of 
antibiotic prophylaxis) as a point of change, but it was 
not possible to confirm that these cases were due to oral 
streptococci because the microbiological data was not 
available.
 A large restriction on the use of antibiotic prophylaxis 
for IE emerges from data from studies in France, where 
antibiotic prophylaxis was limited to high risk groups as 
early as 2002. The analysis used a very precise investigative 
approach to collect data on all cases of IE in different 
regions (15,16). The two studies showed that the incidence 
of IE in three years of investigation (1991, 1999 and 2008) 
was stable at 35, 33 and 32 cases per million, suggesting that 
there was no significant change since the limitation of oral 
antibiotic prophylaxis. Importantly, the number of cases 
caused by oral streptococci was also stable. These data are 
mainly established on the basis of large observational studies 
and have not reported a causal link between restriction 
of antibiotic prophylaxis and incidence of IE. One of 
the reasons that causes a confusion is that the inferior 
clinical results associated with reduced use of antibiotic for 
prophylaxis of IE that have been reported in the registries 
have not been replicated in RCTs. There is growing 
concern that observational studies can be biased in favor of 
an increase in the number of IE after implants of the device, 
Benedetto et al. Controversies in infective endocarditis management
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although this factor has been adapted in some studies, by 
unmatched confounders related to the unmeasurable (and 
un-matchable) judgment of the operating cardiologist. 
Despite long-term controversy and difficulties with 
observational data, randomized trials are highly unlikely 
due to cost, logistics, and ethical debate about real equipoise 
exists to allow the conduction of a placebo-controlled study.
 Currently the ACC/AHA (1) and the European Society 
of Cardiology (ESC) (3,5,17) have a pragmatic approach in 
which the indications are to limit prophylaxis to individuals 
at higher risk based on their underlying heart conditions. 
We believe that this approach represents a correct 
balance between the risks and benefits for the individual 
and the population of using antibiotics. It is important 
to note that the indications do not include patients who 
present with non-cardiac risk factors (e.g., those who are 
immunodeficient) and who may be at increased risk of 
IE and poor outcome if the disease develops. There is an 
emergence of data that suggests in these patients, a tailored 
approach to individual patients remains appropriate, 
according to clinical circumstance (18,19).
Routine imaging
I t  i s  agreed  that  ear ly  pre-operat ive  imaging i s 
recommended in all patients to establish a baseline for the 
diagnosis and treatment of infective endocarditis. There is 
a general consensus to the use of echocardiography, that 
remains an effective and rapid method of imaging, which in 
many cases is diagnostic (1,3,5,6,17) and graded as COR Ia 
LOE: B both in ESC and AHA/ACC guidelines. However, 
it should be emphasized that up to 30% of patients with 
proven IE subsequently are labelled as “possible“ due to 
negative or equivocal results on echocardiography or blood 
cultures (20,21). The use of transthoracic echocardiography 
(TTE) in early stage of diagnosis is the method of imaging 
recommended in the patient with the suspicion of an 
infectious endocarditis involving either a native valve 
(NVE) or a prosthetic valve (PVE). In patients with NVE, 
TTE has a sensitivity between 50% and 90%, while the 
specificity reaches 90%. For suspected PVE, the use of 
TTE has a lower sensitivity, ranging between 40% and 
70%. However, it provides important information in the 
assessment of ventricular size and on its function. The TTE 
adds an additional evaluation on hemodynamic severity of 
valve lesions, diagnosis of anterior prosthetic aorta valve 
abscesses, which can be difficult to visualize with the use 
of transoesophageal echocardiography (TEE). The use of 
TEE is indicated when the TTE is positive but it was not 
sufficient to reach a diagnosis of infectious endocarditis, 
when intracardiac complications are suspected or when 
cables of an implantable device are present. In patients 
with a suspected NVE, the TEE has a sensitivity from 
90% to 100% and specificity of 90% for the detection 
of vegetations and is superior to TTE for detection of 
complications, such as perforations, abscesses, and fistula. In 
ESC guidelines (3,5) TTE should be considered in patients 
with suspected IE, even in cases with positive TTE, except 
in isolated right-sided native valve IE with good quality 
TTE examination and unequivocal echocardiographic 
findings (COR IIa; LOE: C).
Concerns relating to precise diagnosis of PVE still 
persist. In a recent meta-analysis, a reduced aggregate 
sensitivity of 86% was shown [95% confidence interval (CI): 
from 77% to 92%] for TEE in conferring a certainty for the 
diagnosis of IE (22). As such, other imaging modalities are 
emerging to help to make or exclude the diagnosis in cases 
where TEE is not diagnostic. Even when abnormalities are 
detected, it can be difficult to differentiate the presence of 
nodules from small vegetations or to distinguish signs of 
infection from tissue changes that occurred in the post-
operative period. The use of cardiac computed tomography 
(CT) scanning has established itself as the key additional 
modality to be used when echocardiography does not 
provide clearly delineated anatomy information. The CT 
scanning has earned a recommendation to Class II, LOE: B 
for use in IE in ACC/AHA 2014 guidelines for heart disease 
(1,6). Compared to TEE, cardiac CT can be considered 
equivalent or even superior to TEE to demonstrate precise 
features of anatomy and paravalvular complications such as 
paravalvular abscesses or mycotic aneurysms. In addition, 
it is less prone to artifact compared to echocardiography in 
the evaluation of prosthetic valves. The use of concomitant 
CT angiography has become common practice because 
this approach greatly assists surgical strategy planning. 
Its wide use allows the exclusion of a significant coronary 
artery disease in younger patients who can avoid coronary 
angiography. Detection of para-valvular lesions using CT 
imaging is now an important diagnostic criterion in the 
ESC 2015 guidelines (3) on IE despite not yet reaching a 
precise COR and LOE.
New evidence
A large consensus for the diagnosis of IE has occurred with 
the use of combination of CT imaging with metabolic 
Annals of Translational Medicine, Vol 8, No 23 December 2020 Page 5 of 17
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(23):1623 | http://dx.doi.org/10.21037/atm-20-3739
imaging by 18-fluorodeoxyglucose positron emission 
tomography (18FDG-PET) or leukocyte scintigraphy 
(radiolabeled leukocyte single-photon emission computed 
tomography (SPECT). This method is very promising 
because it allows visualisation of regions with metabolic 
activity or inflammation in patients who, according to the 
Duke criteria, have “possible” IE or suspected of cardiac 
device infection. Several reports have demonstrated the 
effectiveness of this method. One study (23) evaluated the 
effect of 18 FDG-PET in 72 patients who had suspected 
PVE reporting diagnosis with an overall sensitivity of 73% 
and a specificity of 80%. The patients who were managed 
with 18FDG-PET as the additional criterion of “abnormal 
prosthetic valve 18FDG-PET signal” showed an increased 
sensitivity of the modified Duke criteria from 70% to 95% 
thus reducing the number of patients with “possible IE” 
from 56% to 32%. In another report (24), 76 of 92 patients 
with suspected PVE or CDI were studied using 18FDG-
PET/CT (angiography), CT and echocardiography 
providing a conclusive diagnosis in 95% of cases overall. 
The addition of this procedure has been associated with 
greater general sensitivity and specificity ranging between 
87% and 90%, respectively, and an increased sensitivity of 
the modified Duke criteria from 51% to 91%.
 Leukocyte scintigraphy with SPECT/CT imaging 
has also been shown to be a valid test with a reported 
sensitivity of 90% and a specificity of 100% in a cohort 
study including 131 patients (25). Another report showed 
inconclusive results using the echocardiography in 39 
patients with suspected PVE. The results with the use of 
18FDG-PET/CT showed a higher sensitivity compared 
to SPECT/CT images, but the SPECT had a greater 
specificity (26). The ESC 2015 guidelines emphasized the 
abnormal meaning of imaging with the use of 18FDG-
PET /SPECT; a positive sign at the site of a prosthetic 
valve (if implanted >3 months previously) is now considered 
an important diagnostic criterion for PVE. However, this 
criterion is not yet included in the AHA/ACC. Relevant 
studies have underlined the fact that the cross-sectional 
routine imaging of the brain, chest, spine and viscera can 
be diagnostic, and can change the IE management. These 
imaging cohort studies suggest that patients with IE have 
a high incidence of subclinical complications, such as 
hemorrhage, embolism, or abscess. In one prospective study 
based on the images of routine cerebral magnetic resonance 
(MRI), abnormalities were identified in 80% of patients and 
simultaneously ‘upgraded’ 26% (14 of 53 patients) diagnosis 
of IE from “possible” to “defined” (27). In another study, 
the use of cerebral angiography CT identified the presence 
of intracranial mycotic aneurysms in 32% of patients with 
left side endocarditis. Subsequently 50% of them had 
endovascular or neurosurgical procedures (28). Iung et al. (29) 
revealed anomalies identified in the spleen, liver, or kidneys 
for 34% of patients on magnetic resonance imaging of the 
abdomen. As a result, evidence of embolism diagnosed 
through the transverse imaging is considered as a minor 
novel diagnostic criterion in the ESC guidelines 2015 (3). 
 Since evidence of cross-sectional imaging, be it cardiac 
CT and 18FDG-PET or SPECT have the potential to 
improve the diagnosis and detection of complications in 
patients with suspected IE, it has been incorporated in 
routine practice for diagnosis in the subset of patients 
termed “Duke possible “and for CDI. However, potential 
disadvantages do exist with these modalities. The main 
drawback is that metabolic imaging cannot be accurate in 
discriminating between barren inflammation and infection, 
and is therefore of limited use in the early postoperative 
period. The literature reports numerous false positives 
for PET/CT imaging after cardiac surgery due to post-
pericardiotomy syndrome, prosthetic valve thrombosis and 
after aortic operation for IE. Two other points to consider 
include access to the advanced imaging procedures, which 
is often limited, hence when emergency intervention is 
required, there is a risk of incurring logistical obstacles that 
may delay definitive surgery. The second is related to the 
fact that at the moment we are unaware of any randomized 
trials that have compared different groups, and it is 
unlikely that such a trial will be conducted. Certainly, the 
identification of which groups of patients from the clinical 
point of view who would benefit the most from advanced 
imaging and through which mode it should be precisely 
executed remains undetermined (Figure 2).
Routine follow-up imaging
It  i s  agreed that  early  post-operat ive imaging is 
recommended in all patients who underwent surgery for 
IE but the recommendations are incongruent. Follow-
up imaging is recommended at 30 days by ESC (3,5,17), 
while 6 weeks to 3 months after valve implantation is 
recommended by the ACC/AHA (1,6,8-10), although the 
general orientation is to perform an echocardiography 
check at the time of hospital discharge. In patients who 
have received mechanical valves, the guidelines do not 
recommend follow-up imaging for those who are stable 
unless there is another indication. In bioprosthetic valve 
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Figure 2 Show the applied strategy of integrated imaging in patients with suspected infective endocarditis (IE). In patients included in the 
subgroup with possible IE after initial evaluation by TTE and TEE a cardiac CT imaging, metabolic imaging or transverse imaging of 
the head and viscera by CT scan or MRI is indicated to achieve a precise early diagnosis. For suspected IE a 18FDG-PET/CT or a cross-
sectional imaging by CT or MRI (or metabolic imaging) scans may assist with detection of complications, such as abscess, mycotic aneurysm, 
infarct, or hemorrhage in patients with definite IE. *, 18F-PDG SPECT/CT is useful in patients with prosthetic valves or cardiac implantable 
electronic devices. IE, infective endocarditis; CT, computed tomography; 18FDG-PET/CT, 18-fluorodeoxyglucose positron emission; MRI, 
magnetic resonance imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; TEE, transoesophageal echocardiography 
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recipients, who are asymptomatic, routine annual TTE 
follow-up imaging is recommended by ESC guidelines (5), 
while ACC/AHA guidelines (1,6) recommend annual TTE 
only after 10 years from the date of implantation of the 
valve. Both guidelines recommend the TTE for the PHV 
dysfunction symptoms/signs irrespective of the implant 
date and in some patients at higher risk of accelerated 
deterioration of the valve even in the absence of symptoms. 
The ESC's recommendation is based on a declaration of 
consent document (30), following the recommendations 
of the Valve Academic Research Consortium-2 (31). In 
patients who received conventional stented/non-stented 
xenograft, the ACC/AHA recommendation is based on 
observations that the incidence of deterioration of structural 
valves is low for bioprosthetic valves in the first 10 years 
after implantation.
Antibiotic therapy
For the cardiologist and the surgeon, the main challenges 
for the success of the antibiotic therapy are represented by 
bacterial tolerance and antibiotic resistance. The persistence 
of phenotypic variants of bacteria despite antibiotic therapy 
may be the cause of tolerance. The result sees a resumption 
of growth and infection once antibiotic concentrations 
decrease. The mechanisms involved in tolerance are 
manifold, including the high bacterial density and poor 
penetration of antibiotics within the vegetations, low 
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metabolic bacterial activity and the production of protective 
biofilm on the prosthetic material (32). The increase in cases 
of Staphylococcus aureus infection has further enhanced 
the problem of antibiotic resistance. For this reason, new 
strategies should be used to prevent and treat IE caused by 
strains that form multidrug-resistant S aureus biofilm. They 
are targeted at to the initial bacterial adhesion inhibition 
to living and inert surfaces, so as to reduce further the 
development of the biofilm. One other action is targeted 
at the interruption of the biofilm architecture as well as to 
anti-pathogenic approaches or signal interference involving 
the inhibition of quorum sensing (33). The prevention 
of bacterial adhesion to subsequent insertion of the 
intracardiac device deserves particular attention. It is crucial 
and can be obtained by using implants coated with various 
adhesion inhibitors. Despite antibiotics, ionic silver, and 
silver nanoparticle exerting inhibitory actions on biofilm 
formation, coated implants were ineffective and poorly 
tolerated in humans. The use of monoclonal antibodies 
such as TRL1068 has shown some promise with regards to 
interrupting the biofilm architecture and is currently under 
evaluation. In an in vivo mouse model a biofilm was created 
through a resistant methicillin S aureus infection which 
was subsequently treated using a combination of TRL1068 
with daptomycin. The association of the two products has 
significantly reduced the adherent bacteria counts compared 
to daptomycin alone (34).
Prolonged antibiotic therapy may lead to toxicity and side 
effects to the patients. Therefore, it is necessary to balance 
the effectiveness of treatment with the overall risk due to 
prolonged antibiotic administration. Emerging evidence 
in support of short-term antibiotic treatment is gradually 
directed at selected patients. In patients with simple IE 
caused by oral streptococci in which renal function is 
preserved, a combination of a penicillin or ceftriaxone with 
an aminoglycoside for a total of 14 days is indicated and 
has been proven to be safe and effective (35). Likewise, a 
2-week monotherapy cycle using penicillin or penicillin-
aminoglycoside in combination demonstrated efficacy 
in patients with right-sided IE who were not sensitive to 
methicillin (36). The use of aminoglycosides, as growing 
data suggest, however, may cause harm without clear 
clinical benefits. Fowler et al. (37) in an RCT, compared 
the use of daptomycin to conventional therapy (penicillin 
or vancomycin with initial gentamicin) in patients with 
right side endocarditis sustained by S aureus bacteremia. 
Daptomycin has been shown to be non-inferior. The 
authors highlighted the occurrence of renal dysfunction 
in 11% of patients in the group treated with daptomycin 
compared to 26% of the group that received conventional 
therapy (37,38).
The use of aminoglycosides has reduced and they were 
removed from guidelines of the AHA/ACC (1,6,8-10) 
and ESC (3,5,17) in patients with methicillin-resistant 
or methici l l in sensit ive S aureus  NVE. Although 
aminoglycosides have gained wide acceptance with 
extensive use in the treatment of enterococci IE; however, 
the increased frequency of resistance (from 25% to 50% 
of isolates in recent studies), alongside the recognition 
of the potential harm, prompted the ESC 2015 steering 
committee to identify ampicillin and ceftriaxone (class IB 
recommendation) as a treatment of choice for Enterococcus 
faecalis resistant to aminoglycosides. There are substantial 
observational studies in support of this direction that led to 
a change in recommendation by the AHA/ACC and ESC. 
In these reports it was shown that ampicillin/ceftriaxone 
was just as effective with reduced levels of nephrotoxicity 
(39,40). Although, current AHA/ACC guidelines (41) 
suggest that the remaining duration of antibiotics should 
be administered (including administration prior to surgery) 
based on level C evidence. However, rationalizing treatment 
with antibiotics in patients who have undergone successful 
surgery and have negative valve cultures can be considered. 
In these patients, the evidence suggests 2 weeks of antibiotic 
therapy may be sufficient for eliminating the qualifying 
pathogen with a margin of safety (42,43) (Figures 3,4).
New evidence
A benefit towards a rapid transition to oral regimens 
of antibiotics with good bioavailability can facilitate a 
reduction in hospital stay. Only 1 published RCT POET 
(Partial Oral Treatment of Endocarditis) (44) that recruited 
400 patients who had endocarditis on the left side of the 
heart caused by streptococcus, Enterococcus faecalis, 
Staphylococcus aureus, or coagulase-negative staphylococci 
compared outcomes between intravenous antibiotics to 
continue intravenous treatment (199 patients) or an oral 
antibiotic treatment switch (201 patients). The primary 
outcome was a composite of all-cause mortality, unplanned 
cardiac surgery, embolic events, or relapse of bacteremia 
with the primary pathogen, from the time of randomization 
until 6 months after antibiotic treatment was completed. 
The primary composite outcome was 12.1% in the patients 
who received intravenously treatment and 9.0% in those 
who were managed with the orally administration of 
Benedetto et al. Controversies in infective endocarditis management
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Figure 3 Includes 20 yrs 4 RCT of IE published from 2001 to 2012. IE, infective endocarditis; IVDU, intravenous drug user; MSSA, 






In patients with NVE 
what is the role of early 
surgery within 48 h of 
randomization?
Patients Population
Included adult patients 
with NVE. Vegetations 
located in left-sided, severe 
valve disease and large 
vegetations
Conclusion
In patients with NVE early 
surgery reduced the composite 
endpoint of in-hospital death 
and embolic events within  
6 weeks from 23% to 3% 
(driven by a reduction in 
embolism)
Conclusion
Daptomycin was noninferior for the 
primary endpoint of clinically successful 
treatment. Clinically significant renal 
dysfunction occurred in 11% of patients 
who received daptomycin and in 26% of 
patients who received standard therapy 
(P=0.004) 
Patients Population
Included adults patients. Presence of 
S aureus bacteremia or IE. Excluded 
adult patients. Presence of intravascular 
material not intended to be removed 
within 4 days or high likelihood of valve 
replacement surgery or death
Patients Population
Included adults patients with left-
sided endocarditis (NVE or PVE).
Excluded adult patients with 
expected surgical intervention 
within 7 days excluded
Conclusion
Aspirin did not reduce the risk of 
embolic events and caused a non 
significant trend toward increased 
incidence of bleeding
Key Findings
Comparison of daptomycin vs. 
vancomycin or anti-staphylococcal 
penicillin with low-dose gentamicin 
for bacteremia or IE caused by 
Staphylococcus aureus
Key Findings
Does aspirin reduce the 
incidence of embolism in 
patients with IE?
Key Findings
In patients with right side NVE caused 
by methicillin-sensitive S aureus is 
effectively a short cycle glycopeptide 
(vancomycin or teicoplanin) in 
combination with gentamicin as 
the combination of cloxacillin and 
gentamicin?
Patients Population
Included adult patients with 
right-side NVE due to IVDUs 
caused by MSSA
Conclusion











antibiotics (3.1 percentage points; 95% confidence interval, 
−3.4 to 9.6; P=0.40) showing that oral antibiotic treatment 
was non-inferior to continued intravenous antibiotic 
treatment (44). 
The benefits associated with the use of outpatient 
parenteral antibiotic therapy (OPAT) can facilitate early 
hospital discharge. OPAT may be initiated in specific 
patients after completion of the first 2 weeks of treatment 
because the risk of complications is reduced. OPAT 
is contraindicated in patients who have heart failure, 
complicated infection, high risk of embolism, neurological 
complications or renal insufficiency (45-47). Early hospital 
discharge is currently being investigated in the ongoing 
RCT OPAT (Outpatient Parenteral Antimicrobial Therapy) 
with an estimated study completion date of December 31, 
2021. The purpose of this study is to investigate the efficacy, 
safety and cost effectiveness of treatments administered at 
the new OPAT unit of the University Hospital of Lausanne 
within the Swiss Health System. The OPAT study recruited 
2,000 patients. The primary end point is the efficacy 
classified 3 months after the end of treatment as the absence 
of fever and no clinical signs of site infection, readmission 
to hospital due to complications related to the infection 
and absence of recurrence of the infection within 3 months 
post-OPAT.
Finally, the use of ciprofloxacin and rifampicin has 
been evaluated in IV drug users (IVDU) with Methicillin-
resistant S aureus NVE. The RCT data demonstrated safety 
and efficacy after oral administration of antibiotics, although 
an increase in rates of resistance to fluoroquinolone limited 
its applicability (48).
Stroke and IE
Stroke occurs as a complication in 20–50% of cases in 
patients with IE (1-3,5). The onset of stroke is a serious 
event because besides causing variable disability, it is an 
independent adverse prognostic factor for survival (49,50). 
Different studies suggest that the risk of stroke is higher at 
diagnosis and decreases rapidly after the use of antibiotic 
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Figure 4 Includes 20 yrs 3 RCT of IE published from 1996 to 1998. IVDU, intravenous drug user; MSSA, methicillin-sensitive 
Staphylococcus aureus; RCT, randomized controlled trial.
Key Findings 
Is ceftriaxone plus gentamicin (for  
2 weeks) superior to ceftriaxone alone 
(for 4 weeks) for IE due to penicillin-
sensitive streptococci?
Key Findings
Is cloxacillin alone as effective 
as cloxacillin plus gentamicin in 
a 2-week course for treatment of 
right- sided S aureus endocarditis in 
IVDUs?
Key Findings 
In patients with right-sided staphylococcal 
endocarditis due to IVDU is effective oral 
administration of ciprofloxacin/rifampicin as 
parenteral therapy (oxacillin or vancomycin, 
plus gentamicin for the first 5 days)?
Patients Population
Included adult patients with 
isolated tricuspid valve 
endocarditis due to IVDUs 
caused by MSSA.
Patients Population
Included adult patients with 
right-sided staphylococcal 
endocarditis due to IVDUs
Conclusion
Oral therapy is as effective as parenteral 
treatment and associated with reduced 
drug toxicity
Patients Population
Included adult patients with 
penicillin-sensitive NVE
Conclusion
Equivalent clinical cure in both groups
Conclusion
No significant benefit from addition of 
gentamicin to cloxacillin (92% cure in 
2-week cloxacillin group, 8% required 
prolonged treatment)
First author








therapy in the initial phase of infection. Dickerman et al. (51) 
reported that the incidence of neurological complication 
drops from 4.82 per 1,000 patient days in the first week 
of therapy to 1.71 per 1,000 patient days in the second 
week. Risk factors identified for embolism are the size of 
the vegetation (>10–15 mm), the involvement of the mitral 
valve, the mobility of the vegetation and S aureus infection.
We have shown that the serious pathological damage 
that often occurs in cauliflower-like friable vegetations of 
valve leaflets, with or without the extension of the lesion 
to the annulus, is an independent factor for embolic 
stroke. However, the key unresolved challenge in the 
contemporary management of IE, keeping the debate alive 
in multidisciplinary heart team decision making, is the 
role of surgery in the prevention of stroke/embolism, and 
patient selection for choosing the optimal time to surgery. 
In the 2015 update of the AHA/ACC guidelines, surgery 
is recommended with an indication as Class IIa for surgery 
to prevent recurrent embolism in patients with previous 
emboli greater ≥10 mm and with high risk of further 
embolism. The risk is defined as persistent or enlarged 
vegetation (17,41). Similarly for the ESC guidelines the 
surgery is categorized as a Class I recommendation, useful 
in preventing recurrent emboli in patients with persistent 
vegetation >10 mm in size (3). Surgery is indicated as 
a Class IIa recommendation in patients at risk of first 
embolism (vegetation >10 mm in size) if associated with 
severe valve regurgitation or stenosis. This AHA/ACC and 
ESC COR and LOE degree is based on RCT evidence (52). 
In patients at high risk of embolism/stroke due to the 
presence of vegetations greater than 15 mm, despite the 
absence of valve dysfunction, surgery for the prevention 
of embolism can be considered. This choice, however, is 
rarely undertaken as the sole indication. In patients who 
have already had a stroke the optimal timing of surgery 
remains a matter of debate, because it is based on a number 
of older studies that have reported poor results in patients 
who underwent early surgery (53). For these, in fact, 
there is a risk of haemorrhagic transformation caused by 
anticoagulation during cardiopulmonary bypass, as well as 
by hypotension that can intervene during surgery. Both of 
these variables can be the cause of theoretical worsening 
of cerebral ischemia. Unfortunately, definitive conclusions 
cannot be given due to the fact that observational studies 
directed towards this topic have generally been small, 
inadequately controlled (49,54) and based on unmatched 
confounders related to the unmeasurable judgment of the 
operating surgeons (2,55-62) (Figures 5,6).
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AHA Guidelines 2015
Heart Failure
I, B Early surgery* is indicated 
in patients with IE who 
present with valve dysfunction 
resulting in symptoms or 
signs of HF I, B Early surgery* 
is indicated in patients with 
PVE with symptoms or signs 
of HF resulting from valve 
dehiscence, intracardiac fistula, 
or severe prosthetic valve 
dysfunction
Prevention of embolism
Ila, B Early surgery* is reasonable in 
patients who present with recurrent emboli 
and persistent or enlarging vegetations 
despite appropriate antibiotic therapy IIa, 
B Early surgery* is reasonable in patients 
with severe valve regurgitation and mobile 
vegetations >10 mm Ib, C Early surgery* 
may be considered in patients with mobile 
vegetations >10 mm, particularly when 
involving the anterior leaflet of the mitral 
valve and associated with other relative 
indications for surgery
Uncontrolled infection
I, B Early surgery* is indicated in 
patients when IE is complicated by 
heart block, annular or aortic abscess, 
or destructivepenetrating lesions HIa, C 
Early surgery* is reasonable for patients 
with relapsing PVE 
I, B Early surgery* should be considered, 
particularly in patients with IE caused by 
fungi or highly resistant organisms (e.g., 
VRE, multidrug-resistant gram-negative 
bacilli)
I, B Early surgery* is indicated for 
evidence of persistent infection 
(manifested by persistent bacteremia 
or fever lasting >5–7 d, and provided 
that other sites of infection and fever 
have been excluded) after the start of 
appropriate antimicrobial therapy
Figure 5 Indications for surgery in AHA. *, defined as “during initial hospitalization and before completion of a full course of antibiotics.” 
HF, heart failure; NVE, native valve infective endocarditis; PVE, prosthetic valve infective endocarditis; VRE, vancomycin-resistant 
Enterococcus.
New evidence
ICE-PCS collaboration (54) reported the largest series 
of 867 patients with IE complicated by ischemic stroke 
syndromes and 198 of these who underwent valve 
replacement surgery post-stroke. The study evaluated the 
effect of 1-year mortality in 58 patients who had early 
surgery compared to those (n=147) who received a later 
operation. The 58 patients undergoing surgery within 
7 days after diagnosis had a trend towards increased in-
hospital mortality rates than those whose surgery was 
managed later (27.1% in early surgery and 19.2% in late 
surgery group, P=0.328; adjusted hazard ratio, 1.138; 95% 
CI, 0.802–1.650). Based on the interpretation of this result, 
the guidelines of AHA/ACC (1,6,41) and ESC (3,5,17) 
suggest surgery as an option to be considered if safe, 
wherever necessary, although stroke remains a common 
reason for avoiding surgery in everyday practice (63). On 
the contrary, in the interpretation of the guidelines based 
on various studies, the transient ischemic attack or silent 
embolism should not delay the indicated surgery for other 
reasons (49). This includes instances when the presence of 
particularly insidious pathogens for which the diagnosis 
can be too late (60). In contrast, patients with cerebral 
hemorrhage or complex stroke resulting in a coma have a 
significantly higher surgical mortality and surgery should be 
postponed for at least 4 weeks if the multidisciplinary heart 
team indicates surgery in these patients (63,64). Finally, 
the management of patients with minor bleeding or mild 
hemorrhagic conversion of an ischemic stroke deserves 
consideration. For this category of patients, the clinical 
scenario can often be complex and the risk/benefit equation 
often challenges any rigid recommendations.
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Surgery
The specific indications for performing surgery in case 
of HVE are the presence of progressive damage to the 
valve and tissues, uncontrolled infection and high risk of 
embolism. Therefore, the first objective of surgery is to 
remove the infected tissue and/or the presence of foreign 
material; to abolish the threat of embolism sources; to 
completely debride the infected paravalvular tissue and any 
cavities that are formed; restore cardiac integrity and valve 
function. Although the use of various surgical techniques 
have been chosen, for example the repair of the mitral valve 
or aortic allograft implantation, however, the results have 
not yet demonstrated a clear long-term advantage of one 
technique over the other. In patients requiring surgery for 
an HVE, regardless of which approach is chosen, evidence 
has shown that long-term outcomes are inferior than 
elective valve surgery. In fact, 10-year survival varies from 
40% to 60% (6,65,66) and the choice of the ideal substitute 
for HVE surgery remains an open debate (2,55-62,67). 
It is not clear whether this delay in mortality refers 
to late complications of prosthetic valve, extracardiac 
manifestations of the disease, or relapse of infection due 
to the persistence of the complex biofilm of the pathogen 
responsible for the HVE. In patients with HVE, the use 
of surgery is currently performed from 50% to 60% with 
reported survival rates at 6 months which are >80% (53,63). 
The indications for surgery were mainly based on the 
benefits, reported in observational and cohort studies, and 
highlighted in patients with valve dysfunction that causes 
heart failure, uncontrolled infection or recurrent embolism. 
The uncontrolled infection is the condition in which the 
infection has had a paravalvular extension, development of 
abscess, or persistent bacteremia. The latter, if manifested in 
a particular patient, can be reason for discussion in the heart 
team shared decision making, when there is mild or relative 
heart failure (68). Figures 2 and 3 show the indications for 
surgery in accordance with the guidelines of the AHA/
ACC and ESC. It is interesting to note that in real world 
situations although there is a significant number of patients 
who have a clear indication for surgery in accordance with 
the guidelines, surgery is still not performed. In a study by 
the ICE-PCS (International Collaboration on Endocarditis-
Potential Cohort Study) registry, this significant percentage 
of patients with left-sided IE, for whom surgical treatment 
is required, reaches 24% (202 of 863) (63). As it emerges 
from the ICE-PCS registry, many predictive factors 
influence the choice to avoid surgery. The avoidance of 
surgery despite HVE was dictated by the presence of liver 
disease [odds ratio (OR) for surgery: 0.16; 95% CI: 0.04 to 
0.64], infection determined by S aureus (OR: 0.50; 95% CI: 
0.30 to 0.85) and stroke before decision to perform surgery 
(OR: 0.54; 95% CI: 0.32 to 0.90). Instead the presence 
of severe aortic regurgitation, abscess and embolization 
was an indication for surgical choice. For 181 patients 
who avoided a surgical procedure, the reasons included an 
unfavorable early prognosis regardless of treatment (34%), 
hemodynamic instability (20%), death before surgery (23%), 
stroke (23%), sepsis (21 %) and surgeon’s refusal to operate 
(26%). Ultimately, in the study of ICE-PCS group, the 
perceived risk of the operation determines the threshold for 
surgical treatment. Surgical procedures for active IE present 
a high risk, with an overall hospital mortality of 20% which 
in many centers can be even higher (63).
New evidence
An important determinant in the choice of surgery in case 
of HVE would come from the improvement of the risk 
assessment models for IE in order to better clarify the 
decision-making process.
The Society of Thoracic Surgeons database was 
used to derive a surgical risk score in patients with IE 
who were likely to have surgery by Gaca et al. (69). The 
model identified 13 risk factors for mortality, including 
emergency status, cardiogenic shock, hemodialysis and 
active endocarditis. The De Feo et al. (70) and Martínez-
Sellés et al. (71) studies incorporated multiple detailed 
parameters of infection, including valve type and organism. 
The PALSUSE score included patients aged ≥70 years 
and the strong extension of the focus of infection with 
substantial intracardiac destruction as risk factors. Other 
factors in PALSUSE are as follows: staphylococcus 
infection, urgent surgery, female gender and EuroSCORE 
(European System for Cardiac Operative Risk Assessment) 
value of ≥10 as predictors of mortality in hospital, with in-
hospital mortality ranging from 0% in patients with a score 
of 0, to 45% in patients with a score >3 (71). The optimal 
timing of surgery remains a controversial cause for debate. 
Advantages and disadvantages are worth considering. On 
the one hand, delaying surgery may allow for a longer 
duration of antibiotic therapy associated with better 
hemodynamic stabilization. Conversely, the postponement 
of the surgical procedure can result in the risk of disease 
progression with the valve destruction, abscess formation, 
heart block, embolic complications and even death. In fact, 
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Aortic or mitral NVE, or PVE 
with severe acute regurgitation, 
obstruction, or fistula causing 
refractory pulmonary edema or 
cardiogenic shock
I, B Urgent†
Aortic or mitral NVE, or PVE 
with severe regurgitation or 
obstruction causing symptoms of 




Locally uncontrolled infection 
(abscess, false aneurysm, fistula, 
enlarging vegetation) I, C Urgent/
Elective Infection caused by fungi or 
multiresistant organisms IIa, B Urgent 
Persisting positive blood cultures 
despite appropriate antibiotic therapy 
and adequate control of septic 
metastatic foci IIa, C Urgent/Elective 




Aortic or mitral NVE, or PVE with persistent 
vegetations > 10 mm after 1 embolic episode 
despite appropriate antibiotic therapy IIa, B 
Urgent Aortic or mitral NVE with vegetations 
>10 mm, associated with severe valve 
stenosis or regurgitation, and low operative 
risk Hla, B Urgent Aortic or mitral NVE, or 
PVE with isolated very large vegetations  
(>30 mm) IIb, C Urgent Aortic or mitral NVE, 
or PVE with isolated large vegetations  
(>15 mm) and no other indication for surgery
Figure 6 Indications for surgery in ESC. †, defined as: emergency surgery = performed within 24 h; urgent surgery = within a few days; 
elective surgery = after at least 1 to 2 weeks of antibiotic therapy. HACEK, Haemophilus species, Aggregatibacter species, Cardiobacterium 
hominis, Eikenella corrodens, and Kingella species; HF, heart failure; NVE, native valve infective endocarditis; PVE, prosthetic valve 
infective endocarditis; VRE, vancomycin-resistant Enterococcus.
for some outcomes such as embolism, the potential gains of 
the surgery are reduced over time (51). In 2012, in a pivotal 
Korean RCT (52), HVE surgery was randomized to early 
surgery (performed within 48 hours of randomization) 
and conventional care in patients with NVE, severe valve 
regurgitation and large vegetations. The patient population 
included in the study reported by Kang et al. (52) were 
young (average age 47 years), with few comorbidities and 
predominantly streptococcal infection. In the results it was 
shown that early surgery was associated with a significant 
reduction in the composite endpoint of death or hospital 
embolism. In addition, surgery was required for more 
than 90% of patients receiving conventional care, thus 
validating indications for surgery. This study is a point of 
reference for the strategy to be applied in HVE and has 
encouraged a trend towards early surgery. However, the 
results found in the study are limited and its applicability is 
uncertain in older populations with multiple comorbidities 
and staphylococcal infection. The findings of the Korean 
study (52) conflict with the results of the studies from 
the ICE-PCS registry (51), which define early surgery as 
being undertaken “during the initial hospitalization for 
IE”. Although early surgery for patients with NVE was 
associated with reduced mortality, this was not true for 
patients with PVE after adjusting for confounding variables 
(55,57).
Cardiac surgeons are faced with a different interpretation 
o f  t h e  e m e r g e n c y / u r g e n c y  c r i t e r i o n  e x p r e s s e d 
in the international guidelines. The emphasis on “early 
surgery” differs significantly between European and US 
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guidelines. The ESC guidelines (3,5,17) distinguishes 
emergency surgery (performed within 24 hours), urgent 
surgery (within a few days) and elective surgery (after 
1–2 weeks of antibiotic therapy), restricting to patients in 
whom urgent surgery is recommended for most cases. On 
the contrary, the AHA guidelines (1,6,8,9,41) define early 
surgery as “during the initial hospitalization and before 
completion of a full course of antibiotics.” Based on our 
experience and considering many reports we can conclude 
that there are no proven benefits in delaying surgery 
once an indication for surgery has been established. The 
choice of timing for the surgery between the same day of 
hospitalization/diagnosis or 48 hours from hospitalization 
for HVE depends on the individual clinical circumstance 
and availability of adequate surgical skills (2,55-62,67,72). 
The current series have shown that it is possible to obtain 
very low mortality in centers of excellence with high 
level experience in managing complex patients where 
the different skills bring together experts in cardiology, 
microbiology and surgery (60). The controversy that 
emerges in the management of the patient with HVE that 
requires the choice of early surgery can only be resolved 
through solid tests that advance the field. RCT level data 
is needed to guide change of practice because data from 
observational studies may lack robustness. Based on these, 
it is more difficult to progress because there is concern 
that observational/cohort studies may be biased in favor of 
conventional mechanical or stented xenograft prosthesis 
by unmatched confounders related to the personal 
consideration of the engaging surgeons (55-59). As can be 
seen from Figure 4 in the last 20 years, only 7 randomized 
studies involving IE patients have been published, most of 
primarily focused on antibiotic therapy and only one on the 
optimal time for the surgical procedure (52). 
 The solution to this conundrum would be to carefully 
define the priorities for new RCTs. They must be 
reasonable and acceptable to the medical community. 
Multicenter studies are demanding and may be limited 
to concerns regarding becoming outliers as experience 
and results vary widely between centers. However, the 
advantage of multicenter registry studies is in the very large 
volume of patients participating, as few centers have the 
volume to perform these studies individually. Furthermore, 
unresolved issues, such as early surgery, may be side-lined 
due to competing/divergent research. This is clearly evident 
in patients with PVE. Should they be clustered with the 
other patients in indications for surgery? Is it recommended 
that all patients with IE and severe valve dysfunction 
undergo surgery, even if they do not have heart failure? 
Finally, as proposed by San Román et al. (68), a randomized 
clinical trial of patients with left-sided IE and high-risk 
characteristics, but without classic surgical indications, 
would be useful. Enrolment groups should include those 
receiving surgery within 48 hours or patients destined for 
conventional care, with mortality as the primary endpoint. 
Although logistically demanding, this study would not only 
be of widespread interest but would be valuable and could 
announce the long-awaited transition from observational 
studies to RCT-level research (56-59).
Conclusions
We have noted several differences between guidelines 
of the AHA/ACC recommendations regarding the 
management of patients with HVE. The existence of 
non-binding recommendations on guidelines seem 
contradictory, especially if indicative for important 
decisions such as the optimal timing of surgical treatment. 
We have also found that a small number of observational 
studies were cited by both guidelines, although supporting 
opposite recommendations. The lack of high-quality 
evidence for the management of patients with HVE is 
not only obvious but is restricted to the management of 
patients who are often in severe clinical conditions. The 
short-term goal would be to increase randomized trials 
for these patients because in their absence, questions 
regarding the validity of these recommendations will 
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